Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 1, 2011

View Archived Issues

New TNF receptor superfamily member 16 antagonists claimed

Novel ionotropic glutamate receptor modulators prepared by Servier

Laboratoires Fournier claims new agents for neurodegenerative diseases

ArQule presents novel inhibitors of cyclin-dependent kinase 7 and CaMK-II

Gene therapy reverses and prevents heart failure after ischemia in preclinical study

Novel metabotropic glutamate mGlu5 receptor agonists reported

Sorrento Therapeutics receives NIH grant for CDI program

Antisense morpholino oligomer holds promise in treatment of Duchenne's muscular dystrophy

Cogane obtains orphan drug status in U.S.

Scynexis synthesizes new agents for hepatitis C

ISTA Pharmaceuticals reports data from phase III Remura trials

Invaron Pharmaceuticals obtains license for Striant

Statin therapy may reduce cardiovascular risk in patients with SLE

RaQualia grants rights for serotonin 5-HT4 partial agonist to CJ CheilJedang

Polaris doses first patient in pivotal phase III ADI-PEG 20 trial

Shionogi & Co. enters agreement to acquire C&O Pharmaceutical Technology

Nippon Chemiphar discontinues development of cathepsin K inhibitor licensed to Velcura

Baxter launches inhaled general anesthetic in Japan

Soligenix expands orBec partnership with Sigma-Tau

Preclinical and clinical data presented on new serotonin 5-HT4 receptor partial agonist PF-04995274

Lilly and Lupin enter collaboration for diabetes therapies

Highlights of Chugai's second quarter of 2011

FDA extends review of Pfizer's sBLA for Prevnar 13

Labopharm and Angelini Group restructure joint venture for Oleptro

FDA approves subcutaneous formulation of Orencia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...